RGEN

Repligen

$176.43

+0.58% 2026-10-19

Health CareS&P 400

1M 3M 6M 1Y 2Y

RGENSPY

+2.3%

-0.3%

+21.3%

+33.7%

YTD

+7.7%

+15.6%

Grades vs sector

Momentum

64th pct in sector

B-

12-1 return: +29.0%
Percentile within its GICS sector across the S&P 1500.

Growth

65th pct in sector

Revenue growth (YoY): +11.9%
Percentile within its GICS sector across the S&P 1500.

Value

4th pct in sector

Forward E/P: 1.5% · EBITDA/EV: 1.5%
Percentile within its GICS sector across the S&P 1500.

Profitability

34th pct in sector

C-

Profit margin: +5.3% · Return on equity: +2.0%
Percentile within its GICS sector across the S&P 1500.

Revisions

no data

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 3 live models right now.

Momentum Top 15

not ranked (outside this model's universe or screens)

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Blend

not in the current book

Key stats

Market cap–

P/E (trailing)–

P/E (forward)–

52-week range– – –

Revenue growth (YoY, latest qtr)–

Dividend yield–

Analyst consensus–

Mean price target–

Valuation & fundamentals

Bottom line

Leans expensive

Model read-out from the numbers below, not advice. Score -2 (DCF counts double).

▼DCF (base case)below the price by 85%

•Piotroski F-score6/9

▲Net debt / EBITDA-1.8x

Discounted cash flow

Bear

$19

-89%

growth -8% · disc. 10.2% · term. 2.0%

Base

$27

-85%

growth -3% · disc. 9.2% · term. 2.5%

Bull

$38

-79%

growth 0% · disc. 8.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Not enough data to run a reverse DCF.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9×

–

Forward P/E

sector median 17.6×

–

EV / EBITDA

sector median 15.8×

–

Price / sales

sector median 3.1×

–

Price / book

sector median 3.5×

–

FCF yield

sector median 4.1%

–

Quality & financial health

Gross margin

53.5%

Operating margin

8.2%

FCF margin

14.3%

Net margin

5.3%

Return on equity

2.0%

Return on invested capital

2.8%

Net debt / EBITDA

-1.8×

Current ratio

9.1×

Interest cover

2.9×

Cash conversion (OCF/NI)

3.2×

Piotroski F-score 6/9 · last two fiscal years

✓ Positive net income✓ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✓ Asset turnover improved

Analysts

No analyst targets available.

Annual history

FY	Revenue	Net income	Free cash flow
2025	$738.3M	$48.9M	$93.9M
2024	$634.4M	$-25.5M	$149.7M
2023	$632.4M	$35.6M	$77.7M
2022	$801.5M	$186.0M	$87.2M
2021	$670.5M	$128.3M	$51.9M
2020	$366.3M	$59.9M	$40.2M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -2.7%.

Earnings

Next report: 2026-10-27 · before open · EPS est 0.46

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-07-28	0.45	0.54	+20.4%
2026-05-05	0.39	0.48	+22.9%
2026-02-24	0.44	0.49	+10.4%
2025-10-28	0.42	0.46	+10.6%
2025-07-29	0.39	0.37	-5.0%
2025-04-29	0.35	0.39	+11.4%
2025-02-20	0.41	0.44	+7.9%
2024-11-12	0.33	0.43	+29.4%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$204.1M	+11.9%
2026-03-31	$194.3M	–
2025-12-31	$197.9M	–
2025-09-30	$188.8M	–
2025-06-30	$182.4M	–

Analyst actions

Canaccord Genuity

2026-10-19 · main

Hold → Hold
PT $180

Barclays

2026-10-07 · main

Overweight → Overweight
PT $225

UBS

2026-09-09 · main

Buy → Buy
PT $225

Wells Fargo

2026-07-30 · main

Overweight → Overweight
PT $185

JP Morgan

2026-07-29 · main

Overweight → Overweight
PT $175

Benchmark

2026-07-07 · up

Hold → Buy
PT $185

Insider trades

Loeillot Olivier

Director, Chief Executive Officer · 2026-10-05

SELL
$238.3K

Loeillot Olivier

Director, Chief Executive Officer · 2026-10-05

SELL
$798.4K

Loeillot Olivier

Director, Chief Executive Officer · 2026-09-24

SELL
$1.6M

Loeillot Olivier

Director, Chief Executive Officer · 2026-09-24

SELL
$863.0K

Loeillot Olivier

Director, Chief Executive Officer · 2026-09-21

SELL
$976.7K

Loeillot Olivier

Director, Chief Executive Officer · 2026-09-04

SELL
$503.5K

Loeillot Olivier

Director, Chief Executive Officer · 2026-08-20

SELL
$976.7K

None

None · None

SELL
–

None

None · None

SELL
–

None

None · None

SELL
–

None

None · None

SELL
–

News

Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know

StockStory · Oct 16

Repligen to Report Third Quarter 2026 Financial Results

GlobeNewswire · Oct 13

Why Are Freshworks (FRSH) Shares Soaring Today

StockStory · Oct 06

Repligen Insider Sold Shares Worth $1,036,654, According to a Recent SEC Filing

MT Newswires · Oct 06

Repligen Closes BioLife Solutions Acquisition

MT Newswires · Oct 06

Repligen Completes Acquisition of BioLife Solutions

GlobeNewswire · Oct 06

Freshworks Set to Join S&P SmallCap 600

PR Newswire · Oct 05

Freshworks stock climbs on S&P SmallCap 600 inclusion

Investing.com · Oct 05

Stats refreshed 2026-10-19 19:02:57 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Coteau Systematic StrategiesSystematic equity research and model portfolios.
Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.

What is Coteau?Disclaimer Terms Privacy Data status